Weill Cornell Medicine researchers received a $1 million PCF Challenge Award to develop an AI model for early detection of treatment-resistant prostate cancer subtypes.
Key Details
- 1Dr. Ekta Khurana leads the project, collaborating with Memorial Sloan Kettering Cancer Center.
- 2The team received a $1 million, two-year Prostate Cancer Foundation Challenge Award.
- 3Research focuses on AI models trained on pathology slides, gene activity, and treatment outcomes.
- 4Project aims to identify patients with tumors likely to develop resistance early so they can be matched to appropriate trials.
- 5Validation of the developed AI model in clinical trials is planned for a follow-on project.
Why It Matters
Developing AI tools to distinguish treatment-resistant tumor subtypes could significantly improve personalized care and trial selection for prostate cancer, addressing a pressing clinical need. Integration of pathology, genomics, and AI in this way is at the forefront of imaging-based precision medicine.
Source
EurekAlert
Related News
•EurekAlert
AI Accelerates Radiopharmaceuticals, Boosts Personalized Dosimetry in Cancer
Machine learning is driving advancements in radiopharmaceutical drug discovery and optimizing patient-specific dosimetry for precision cancer therapy.
•EurekAlert
Physicians Overly Trust Erroneous AI, Ignore Contradictory Evidence
Physicians tend to trust incorrect AI advice, even when evidence contradicts it, suggesting risks in clinical decision-making with AI tools.
•EurekAlert
Concerns Raised Over Unverified Datasets in AI Health Prediction Models
A new study finds widely used AI health prediction models are built on datasets with unverifiable origins, raising safety and validity concerns.